Skip to content

Clinical trials

Antiphospholipid Syndrome trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Antiphospholipid Syndrome Country / region: China Clear all

24 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20201
20211
20223
20233
20245
20258
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting14
Not yet recruiting3
Unknown status3
Active, not recruiting1
Completed1
Terminated1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
China Immunotech (Beijing) Biotechnology Co., Ltd.6
Institute of Hematology & Blood Diseases Hospital, China3
Peking Union Medical College Hospital2
Peking University Third Hospital2
Ruijin Hospital2
Bioray Laboratories1
Children's Hospital of Fudan University1
First Affiliated Hospital of Wenzhou Medical University1
Peking University People's Hospital1
Qilu Hospital of Shandong University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Antiphospholipid Syndrome24
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis14
Lupus Erythematosus, Systemic14
Myositis13
Scleroderma, Systemic12
Sjogren's Syndrome11
Autoimmune Diseases3
Lupus Nephritis3
Immunoglobulin G4-Related Disease2
Recurrence2

Trials

Showing 51 to 24 of 24. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.